Test Catalog

Test ID: MCSTP    
MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor

Useful For Suggests clinical disorders or settings where the test may be helpful

Assisting in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with solid tumors


Identifying somatic alterations including single nucleotide variants (SNV), small insertions/deletions (INDEL), gene amplifications, fusions, and splice variants in genes known to be associated with the tumorigenesis of solid tumors


Assessment of microsatellite instability and tumor mutational burden status

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test uses targeted next-generation sequencing to estimate tumor mutational burden (TMB), determine microsatellite instability (MSI) status, and identify somatic sequence variants, gene amplifications, fusions, and specific transcript variants in solid tumors. This panel includes a DNA subpanel for the detection of sequence alterations in 514 genes and amplification of 59 genes as well as an RNA subpanel for the detection of fusions involving 55 genes and specific splice variants involving EGFR, AR, and MET. See Genes Interrogated by MayoComplete Solid Tumor Panel in Special Instructions for details regarding genes interrogated by this test.


Note: This test is performed to evaluate for somatic (ie, tumor-specific) alterations within the genes listed. Although germline (ie, inherited) alterations may be detected, this test cannot distinguish between germline and somatic alterations with absolute certainty. Follow-up germline testing using whole blood can be performed for confirmation of suspected clinically relevant germline alterations. Germline testing should be performed along with genetic counselling.


In addition to single nucleotide variants (SNV) and small insertions/deletions sequence variants, this test also identifies gene amplifications, fusions, and splice variants. Tumor mutational burden (TMB) and microsatellite instability (MSI) status are also determined as part of this test and are often clinically actionable for determining the efficacy of immunotherapy in solid tumors.


For each case, a quantitative value for TMB and qualitative assessments for TMB (TMB-Low, TMB-High) and MSI (MSS, MSI-H) are reported.

Additional Tests Lists tests that are always performed, at an additional charge, with the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
SLIRVSlide Review in MGNo, (Bill Only)Yes

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, slide review will always be performed at an additional charge to ensure specimen adequacy.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Sequence Capture and Targeted Next-Generation Sequencing (NGS)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

MayoComplete Solid Tumor Panel

Aliases Lists additional common names for a test, as an aid in searching

Cancer NGS Panel
Cancer Panel
Fusion panel
Gene fusion
Gene fusion targets
Gene rearrangement
Large Cancer Panel
Large Somatic NGS Cancer Panel
Mayo Clinic Large Cancer Panel
Next Gen Sequencing Test
Oncology panel
Sequence variant
Splice variant
Single nucleotide variant
Transcript variant
Comprehensive Genomic Profiling
Copy number variant
Gene amplification
Microsatellite Instability
Tumor mutational burden